Table 1.
Patient Characteristics
| <74 Gy (n = 224) | 74 - 76 Gy (n = 270) | >76 Gy (n = 173) | |
|---|---|---|---|
| Age (y) | |||
| Mean | 69 | 69 | 68 |
| Median | 70 | 70 | 69 |
| Range | 55-86 | 45-84 | 49-83 |
| T-stage | |||
| T1-T2 | 202 (90%) | 245 (91%) | 159 (92%) |
| T3-T4 | 22 (10%) | 25 (9%) | 14 (8%) |
| iPSA, ng/mL | |||
| 0-10 | 52 (23%) | 57 (21%) | 73 (42%)* |
| >10-20 | 117 (52%) | 146 (54%) | 74 (43%)* |
| >20 | 55 (25%) | 67 (25%) | 26 (15%)* |
| Gleason Score | |||
| 2-6 | 137 (61%) | 153 (57%) | 67 (39%)* |
| 7 | 77 (34%) | 96 (36%) | 91 (53%)* |
| 8-10 | 10 (4%) | 21 (8%)* | 15 (9%)* |
| RT Dose, Gray | |||
| Mean | 71.4 | 75.6* | 80.5* |
| Median | 71.6 | 75.8* | 80.0* |
| Range | 67.4-73.9 | 74.3-75.9 | 76.2-82.1 |
| Follow-up, months | |||
| Mean | 87 | 84 | 61* |
| Median | 85 | 87 | 65* |
| Range | 11-185 | 4-152 | 5-161 |
Abbreviations: Gy = Gray; RT = radiotherapy; iPSA = initial preradiotherapy prostate specific antigen level.
*
P-value <0.05 when compared to <74 Gy group.